Alpine Immune Sciences (Nasdaq:ALPN) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ALPN Aperçu des actions

Operates as a clinical-stage biopharmaceutical company.

ALPN analyse fondamentale
Score flocon de neige
Évaluation	1/6
Croissance future	2/6
Performances passées	0/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Les revenus devraient augmenter 34.24% par an

Analyse des risques

Les bénéfices devraient diminuer en moyenne de 9.9% par an au cours des 3 prochaines années

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

Les actionnaires ont été dilués au cours de l'année écoulée

Volatilité du cours de l'action au cours des 3 derniers mois

Alpine Immune Sciences, Inc. Concurrents

Crinetics Pharmaceuticals

NasdaqGS:CRNX

US$4.3b

Apellis Pharmaceuticals

NasdaqGS:APLS

US$4.6b

ADMA Biologics

NasdaqGM:ADMA

US$4.2b

Alkermes

NasdaqGS:ALKS

US$4.6b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Alpine Immune Sciences
Historique des cours de bourse
Prix actuel de l'action	US$64.97
Plus haut sur 52 semaines	US$65.00
Plus bas sur 52 semaines	US$8.33
Bêta	0.97
1Variation sur 1 mois	0.65%
Variation sur 3 mois	113.79%
Variation sur 1 an	518.17%
3Variation sur 3 ans	520.53%
Variation sur 5 ans	1,270.68%
Évolution depuis l'introduction en bourse	580.31%

Nouvelles et mises à jour récentes

Recent updates

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Apr 11

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Mar 21

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Mar 20

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Mar 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Feb 07

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Dec 19

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Sep 23

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Aug 09

Alpine: Rest Before Rallying Again

Apr 25

Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?

Apr 12

Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt

Sep 18

Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%

Aug 18

Rendement pour les actionnaires

	ALPN	US Biotechs	US Marché
7D	0.03%	3.5%	3.0%
1Y	518.2%	21.0%	24.6%

Rendement vs Industrie: ALPN a dépassé le secteur US Biotechs qui a rapporté 15.7 % au cours de l'année écoulée.

Rendement vs marché: ALPN a dépassé le marché US qui a rapporté 25.6 % au cours de l'année écoulée.

Volatilité des prix

Is ALPN's price volatile compared to industry and market?
ALPN volatility
ALPN Average Weekly Movement	13.8%
Biotechs Industry Average Movement	10.4%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	3.1%

Cours de l'action stable: Le cours de l'action de ALPN a été volatil au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de ALPN ( 14% ) est restée stable au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2007	142	Mitch Gold	www.alpineimmunesciences.com

Alpine Immune Sciences, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Alpine Immune Sciences se comparent-ils à sa capitalisation boursière ?
ALPN statistiques fondamentales
Capitalisation boursière	US$4.46b
Bénéfices(TTM)	-US$36.84m
Recettes(TTM)	US$56.52m

78.9x

Ratio P/S

-121.0x

Ratio P/E

Le site ALPN est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
ALPN compte de résultat (TTM)
Recettes	US$56.52m
Coût des recettes	US$83.78m
Marge brute	-US$27.26m
Autres dépenses	US$9.58m
Les revenus	-US$36.84m

Derniers bénéfices déclarés

Mar 31, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-0.54
Marge brute	-48.23%
Marge bénéficiaire nette	-65.17%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de ALPN?

Voir les performances historiques et les comparaisons

ALPN Aperçu des actions

Récompenses

Analyse des risques

Alpine Immune Sciences, Inc. Concurrents

NasdaqGS:CRNX

US$4.3b

NasdaqGS:APLS

US$4.6b

NasdaqGM:ADMA

US$4.2b

NasdaqGS:ALKS

US$4.6b

Historique des prix et performances

Nouvelles et mises à jour récentes

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

Consensus estimates of losses per share improve by 20%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Alpine Immune Sciences Files Form 15

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from NASDAQ Composite Index

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders.

Alpine Immune Sciences, Inc.(NasdaqGM:ALPN) dropped from S&P TMI Index

Consensus estimates of losses per share improve by 20%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement

Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion.

New minor risk - Share price stability

Alpine Immune Sciences, Inc Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts

Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 10% to US$37.00

Alpine Immune Sciences, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug

Price target increased by 9.5% to US$33.57

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up

Price target increased by 11% to US$31.83

Price target increased by 12% to US$30.67

Executive Chairman & CEO exercised options and sold US$1.8m worth of stock

Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up

Executive Chairman & CEO notifies of intention to sell stock

Consensus revenue estimates increase by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $149.9968 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

Alpine Immune Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Alpine Immune Sciences, Inc. Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis

New minor risk - Share price stability

Alpine Immune Sciences, Inc. Announces Appointment of Wolfgang Dummer as Chief Medical Officer

We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth

Alpine Immune Sciences, Inc. Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)

Consensus estimates of losses per share improve by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

Consensus revenue estimates fall by 33%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Alpine Immune Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

Alpine Immune Sciences Terminates Enrollment of Davoceticept Clinical Studies (NEON-1 and NEON-2)

Price target decreased to US$18.33

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $100.0041 million.

Alpine Immune Sciences drops 13% after hours on $100M stock offering

Alpine Immune Sciences, Inc. Provides Clinical Updates for Its Two Wholly Owned Programs, ALPN-303 and davoceticept

Consensus EPS estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt

Alpine Immune Sciences, Inc. Announces Board Changes

Alpine Immune Sciences Appoints Andrew S. Sandler as Chief Medical Officer

Alpine Immune Sciences, Inc. Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab